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Background: Aggregation and aggregation-mediated formation of toxic alpha synuclein (aSyn) species have been
linked to the pathogenesis of sporadic and monogenic Parkinson’s disease (PD). A novel H50Q mutation of aSyn,
resulting in the substitution of histidine by glutamine, has recently been identified in PD patients. We have
previously shown that the lipid peroxidation product 4-hydroxy-2-nonenal (HNE) induces the formation of
HNE-aSyn adducts, thereby promoting aSyn oligomerization and increasing its extracellular toxicity to human
dopaminergic neurons. Intriguingly, we identified histidine 50 (H50) of aSyn as one of the HNE modification target
residues. These converging lines of evidence support the hypothesis that changes in H50 via posttranslational
modification (PTM) and mutation trigger the formation of aggregated, toxic aSyn species, which interfere with
cellular homeostasis. In the present study, we aim to elucidate 1) the role of H50 in HNE-mediated aSyn aggregation
and toxicity, and 2) the impact of H50 mutation on aSyn pathology. Besides the PD-related H50Q, we analyze a
PD-unrelated control mutation, in which H50 is replaced by an arginine residue (H50R).
Results: Analysis of HNE-treated aSyn revealed that H50 is the most susceptible residue of aSyn to HNE modification
and is crucial for HNE-mediated aSyn oligomerization. Overexpression of aSyn with substituted H50 in H4 neuroglioma
cells reduced HNE-induced cell damage, indicating a pivotal role of H50 in HNE modification-induced aSyn toxicity.
Furthermore, we showed in vitro that H50Q/R mutations substantially increase the formation of high density and
fibrillar aSyn species, and potentiate the oligomerization propensity of aSyn in the presence of a nitrating agent.
Cell-based experiments also revealed that overexpression of H50Q aSyn in H4 cells promotes aSyn oligomerization.
Importantly, overexpression of both H50Q/R aSyn mutants in H4 cells significantly increased cell death when compared
to wild type aSyn. This increase in cell death was further exacerbated by the application of H2O2.
Conclusion: A dual approach addressing alterations of H50 showed that either H50 PTM or mutation trigger aSyn
aggregation and toxicity, suggesting an important role of aSyn H50 in the pathogenesis of both sporadic and
monogenic PD.
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Parkinson’s disease (PD) is the most prevalent neurode-
generative movement disorder worldwide. The disease is
associated with a progressive loss of dopaminergic
neurons in the substantia nigra pars compacta. An
important neuropathological hallmark is the formation
of eosinophilic inclusions called Lewy bodies (LB) and
Lewy neurites in brains of PD patients, mainly consisting
of aggregated alpha synuclein (aSyn), along with other
proteins such as neurofilament subunits and ubiquitin [1].
The etiology of PD has not been fully understood. Envir-
onmental factors and genetic variants, which are proposed
to affect neuronal function and eventually lead to degen-
erative processes, have been linked to an increased risk for
PD. In particular, molecular and cellular disturbances in-
cluding oxidative stress, mitochondrial impairment, and
abnormal protein processing have been closely associated
with PD [2].
Although the majority of PD cases are of unknown
(sporadic) etiology, distinct genetic mutations of different
genes account for approximately 10% of PD cases [3]. In
particular, five point mutations in the coding sequence of
the aSyn gene (SNCA) have been linked to autosomal
dominant inherited PD, including the intensively studied
A53T, A30P, and E46K mutations [4-6], and the very
recently discovered H50Q and G51D mutations [7-9]. In
addition, duplication and triplication of SNCA have been
identified in familial forms of PD [10-12], suggesting that
overexpression of the aSyn protein disturbs neuronal
homeostasis. Furthermore, genome wide association stud-
ies revealed that genetic variants of SNCA are closely
linked to sporadic PD [13,14]. The pathological relevance
of aSyn in PD is further supported by the observation
that aggregated and posttranslational modified aSyn is
the major protein component in LB [15]. All these lines of
evidence support a crucial role of aSyn, particularly of its
aggregated forms, in the pathogenesis of PD.
Physiologically, aSyn is a soluble protein and is pre-
dominantly localized in neurons at presynaptic terminals
in close proximity to synaptic vesicles [16]. aSyn aggre-
gation is a process, in which the physiological soluble
aSyn proteins change in conformation to produce patho-
logical aggregated forms. Aggregated aSyn species in-
clude oligomers and fibrils, characterized by increased
beta sheet content, insolubility, and detergent resistance
[17]. Yet, it has not been clarified which factors trigger
aggregation of aSyn and which aggregated aSyn species
interfere with neuronal homeostasis in PD pathogenesis.
Accumulating evidence supports that oxidative stress is
an important modifier of aSyn aggregation. Oxidative
stress is characterized by the accumulation of reactive
oxygen/nitrogen species (ROS/RNS), which affect biomol-
ecules, leading to posttranslational modifications (PTMs)
of proteins and lipid peroxidation. Some of the generatedaldehyde products during lipid peroxidation/degradation,
such as 4-hydroxy-2-nonenal (HNE), are highly reactive to
proteins and further trigger PTMs by forming aldehyde
adducts on target proteins [18]. We have recently shown
that ROS/RNS and HNE modify aSyn and promote the
aggregation of aSyn [19]. Importantly, HNE modification
of aSyn enhances the neurotoxicity of aSyn [20,21], in par-
ticular to human dopaminergic neurons [19]. Using mass
spectrometry, we identified histidine 50 (H50) of aSyn as
one of the target residues of HNE modification. Interest-
ingly, a novel SNCA mutation, resulting in an amino acid
exchange of H50 with a glutamine residue (H50Q), was
recently reported in two PD patients [7,9]. These conver-
ging lines of evidence suggest that alterations of H50, via
either PTM or genetic mutation, influence the aggregation
propensity of aSyn and eventually induce cell damage.
To elucidate the relevance of H50 for aSyn pathology,
in particular for aSyn aggregation and cytotoxicity, we
investigated the role of H50 in 1) HNE-mediated, and 2)
H50 mutation-induced aSyn pathology. In addition to
H50Q, we analyzed a PD-unrelated mutation in order to
answer the question of whether the potential changes
induced by the PD-related H50Q mutation are due to
the loss of H50, or are attributed to the specific effect of
the glutamine residue. To this end, we replaced H50 by
an arginine residue (H50R), which belongs to the group
of polar and basic amino acids like histidine. Our results
show that both posttranslational and genetic modifi-
cations of aSyn at the specific H50 residue increase the
aggregation propensity and toxicity of aSyn.
Results
aSyn H50 is the most reactive residue for HNE modification
HNE, a lipid peroxidation product, reacts with histidine,
cysteine, and lysine residues of proteins, leading to the
formation of HNE-protein adducts [18]. Since aSyn does
not have cysteine residues, the only histidine residue
(H50) and 15 lysine residues are potential targets for HNE
modification. Recently, we showed that H50 of aSyn is a
target residue for HNE modification, although it is not the
only possible modification site in aSyn [19]. Indeed, HNE
modifications of Lys 60 and Lys 96 have also been de-
scribed [22]. Thus, our first aim was to elucidate the role
of H50 for HNE modification in aSyn.
We applied site-directed mutagenesis to exchange the
H50 residue and to produce two recombinant aSyn H50
mutants, i.e. H50Q and H50R. HNE concentration ranges
in vivo from 0.1 - 3 μM under physiological conditions
and may increase up to 10 - 5000 μM under pathological
conditions of increased oxidative stress [18,23]. In order
to analyze the reactivity of H50 to HNE, we incubated
recombinant wild type (WT) and H50Q/R mutant
aSyn with pathologically relevant HNE concentrations
(50 – 3000 μM). The addition of one HNE molecule
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mass increase of 156 Da. Matrix-assisted laser-desorption-
ionization time-of-flight mass spectrometry (MALDI-TOF
MS) analysis of GluC-digested WT aSyn exposed to HNE
revealed HNE modification of the H50 containing peptide
47GVVHGVATVAE57 (Figure 1A). The shift from un-
modified (*) to modified peptide (↓) increased in a HNE
concentration-dependent manner. Both H50 mutants
(H50Q/R) completely abolished HNE modification of the
corresponding residue 50 containing peptides (Figure 1B).
MALDI-TOF MS analysis of full-length aSyn revealed
that HNE addition to WT aSyn is already detectable at a
HNE concentration of 50 μM (Figure 1C). Incubation of
WT aSyn with HNE at low concentrations (50 - 200 μM)
resulted in the addition of a single HNE molecule. HNE
concentrations from 500 to 3000 μM induced the forma-
tion of additional HNE adducts in WT aSyn, indicating
the existence of more than one modifiable amino acid
residue at high HNE concentrations. In contrast to WT
aSyn, HNE adducts were barely detectable in aSyn H50
mutants (H50Q/R) exposed to low HNE concentrations
(50 - 200 μM). Only high concentrations of HNE applied
to H50 mutant aSyn led to the formation of HNE adducts.
This result revealed that other modifiable residues of aSyn
(e.g. lysine residues) exhibit a lower reactivity to HNE andFigure 1 HNE modification of WT and H50 mutant aSyn. A) Recombinan
24 h was digested by GluC in order to measure HNE modification of the H50
modification of this peptide (*observed monoisotopic mass to charge ratio m
monoisotopic m/z: 1194). B) aSyn H50Q and H50R mutations completely abo
residue 50. Only unmodified peptides, i.e. 47GVVQGVATVAE57 (*observed mon
monoisotopic m/z: 1057) of the H50R aSyn, are observed. C) Recombinant full-le
for 24 h and analyzed by MALDI-TOF MS. Unmodified (*) and HNE-modifie
of 156 Da are indicated. H50Q/R mutations reduce the formation of aSyn-
low concentrations (50 - 200 μM).thus indicate that H50 is the initial target residue of HNE
modification.
aSyn H50 is the crucial residue for HNE-mediated
oligomerization
HNE triggers the oligomerization of aSyn [19]. As lysine
residues may also be involved in HNE modification, we
asked whether HNE modification of H50 is the major
factor for HNE-mediated oligomerization. We exposed
recombinant human WT and H50Q/R aSyn to different
HNE concentrations and investigated the HNE-mediated
oligomerization by SDS-PAGE followed by Western blot
(WB) analysis (Figure 2A and B) and size exclusion
chromatography (SEC) (Figure 2C and D). We observed
that SDS-resistance of aSyn oligomers is dependent on
the applied HNE concentration. SDS-resistant oligomers
of WT aSyn were detectable after exposure to 3 mM
HNE (Figure 2A). Importantly, at the same HNE con-
centration, i.e. 3 mM, H50 mutations reduced the for-
mation of HNE-induced, SDS-resistant aSyn oligomers
(Figure 2B). This effect was reproducibly detected using
different antibodies raised against distinct aSyn antigens.
Using SEC analysis, we observed an increase in the
formation of soluble WT aSyn oligomers after HNE
exposure (Figure 2C). In accordance to the results oft WT aSyn treated with different concentrations of HNE (0 - 3000 μM) for
containing peptide 47GVVHGVATVAE57 by MALDI-TOF analysis. The
/z: 1038) by HNE leads to a mass increase of 156 Da (↓ observed
lish HNE modification of the corresponding peptides containing the
oisotopic m/z: 1029) of the H50Q aSyn and 47GVVRGVATVAE57 (*observed
ngth WT and H50Q/R aSyn were treated with different HNE concentrations
d (↓) aSyn (WT, H50Q, and H50R) with a characteristic mass difference
HNE-adducts, particularly they prevent the modification by HNE at
Figure 2 HNE-induced aggregation of WT and H50 mutant aSyn. A) Recombinant human WT aSyn was treated with 0, 0.2, 1, and 3 mM HNE
for 24 h and analyzed by SDS-PAGE followed by WB using an antibody against aSyn (Syn-1). The formation of SDS-resistant aSyn oligomers as
indicated shows an increase in a HNE-concentration dependent manner. M: aSyn monomers; D: aSyn dimers; O: aSyn oligomers. B) Recombinant
human WT and H50Q/R aSyn were treated with 3 mM HNE for 24 h and analyzed by SDS-PAGE and WB. H50Q/R mutations decrease the formation of
HNE-induced SDS-resistant aSyn oligomers as probed by two different antibodies raised against distinct aSyn antigenes (Syn-1 antibody, left, and
SNCA antibody, right). C) WT, H50Q, and H50R aSyn were treated with 3 mM HNE for 24 h and subsequently analyzed by SEC in order to assess the
formation of soluble oligomers. aSyn monomers (M) and oligomers (O) are distinguished by different retention times. D) Area ratio of oligomeric to
monomeric fraction in HPLC chromatograms of SEC was calculated for aSyn incubated with 0.2, 1, or 3 mM HNE. H50 mutations reduce the formation
of HNE-induced soluble oligomers. Significance was determined by a one way ANOVA Tukey’s Multiple Comparison Test. n = 3. Error bars = SEM.
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decreased the formation of HNE-mediated soluble
oligomers (Figure 2D). While SDS-PAGE detects SDS-
resistant oligomers (both soluble and insoluble), SEC
examines soluble oligomers (both SDS-resistant and
non-resistant). Both approaches provided consistent re-
sults, indicating that H50 is the initial factor contributing
to HNE-induced oligomerization of aSyn.
The substitution of aSyn H50 reduces HNE-induced
cytotoxicity
HNE modification increases the cytotoxicity of aSyn
when applied to cells extracellularly [19]. Furthermore,
HNE modification of intracellularly overexpressed aSyn
was shown in cells exposed to extracellular HNE [22].Thus, we asked whether H50, the most reactive target
residue of aSyn for HNE modification (as described
above, Figure 1), influences the susceptibility of aSyn
overexpressing cells to HNE exposure. To address this
question, we generated pcDNA3.1 plasmids encoding
human WT or H50Q/R mutant aSyn for transient trans-
fection in mammalian cells. To reduce the interference
between endogenous and overexpressed aSyn variants,
we chose human H4 neuroglioma cells, which only
express very low levels of endogenous aSyn. aSyn over-
expression was confirmed via immunocytochemistry
(ICC) and flow cytometric analysis (Figure 3A, B and C).
The proportion of aSyn transfected cells showed a time
dependent increase, reaching 39 - 48% 36 h after transfec-
tion (Additional file 1: Figure S1). H4 cells transfected
Figure 3 HNE-induced cytotoxicity in WT and H50 mutant aSyn overexpressing cells. A) Expression of aSyn in H4 cells transiently
transfected with WT aSyn and H50 mutants (H50Q/R) was confirmed by ICC using an antibody against human aSyn (green) and counterstaining
by DAPI (blue). B) Transfection efficiency and C) aSyn expression levels in H4 cells transfected with WT aSyn and H50 mutants were assessed via
flow cytometry at the time point of HNE treatment (24 h posttransfection). WT and H50Q/R aSyn transfected cells show an equal proportion of
aSyn overexpressing cells (B) as well as comparable aSyn expression levels (C). Significance was determined by one way ANOVA Tukey’s Multiple
Comparison Tests. n = 3. Error bars = SEM. D) H4 cells transiently transfected with mock, WT, and H50Q/R aSyn were treated with different HNE
concentrations (20 – 60 μM) for 12 h and cellular viability was measured by MTS assay. HNE induces a dose-dependent reduction of cell viability.
H50Q/R mutant aSyn transfected cells appear to be more resistant to HNE than WT aSyn transfected cells. Significance was determined by two
way ANOVA Bonferroni Multiple Comparisons. n = 8. Error bars = SEM.
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comparable transfection rate for all measured time
points (17 – 36 h posttransfection, Additional file 1:
Figure S1C). No significant differences in both transfec-
tion efficiency and aSyn expression levels were detected
24 h after transfection, when we started the treatment
experiments (Figure 3B and C). We incubated WT and
H50Q/R mutant aSyn, as well as mock transfected cells,
with different concentrations of HNE and measured cell
damage by using MTS viability assay. While HNE exposedWT aSyn overexpressing cells showed a reduced viability
compared to mock-transfected cells for the HNE concen-
trations used (20 – 60 μM), in particular for 40 μM HNE,
cell damage of H50Q and H50R overexpressing H4 cells
exposed to the same HNE concentrations was less pro-
nounced (Figure 3D). The complementary flow cytometric
analysis of transfected H4 cells treated with HNE sup-
ported that H50 mutant aSyn overexpressing cells, in par-
ticular the aSyn H50R overexpressing cells, are more
resistant to HNE exposure than WT aSyn transfected cells
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the exchange of the H50 residue attenuates the toxic effect
of HNE, supporting the essential role of H50 HNE modifi-
cation for HNE-induced cytotoxicity.
H50 mutations increase the aggregation propensity of
aSyn both in vitro and in cells
Modification of H50 is crucial for HNE-induced aSyn
oligomerization. Thus, we asked whether the alteration
of H50 through genetic point mutation, particularly the
novel reported H50Q mutation, also influences the ag-
gregation propensity of aSyn. In addition to H50Q, we
analyzed a non PD-related control mutation (H50R) to
specify whether changes caused by H50Q mutation are
due to the loss of H50 or attributed to the specific effect
of the glutamine residue.
To evaluate the intrinsic aggregation propensity of
mutant H50 variants, we applied sucrose density gradi-
ent centrifugation (SDGC), and used the collected frac-
tions for dot blot analysis in order to detect aggregation
of aSyn. To optimize the separation range of the density
gradient, we first analyzed control samples including
WT monomeric aSyn (WT, Figure 4, upper panel), highly
oligomerized HNE-modified WTaSyn (HNE-aSyn, Figure 4
lower panel), nitrated WT aSyn (n-aSyn, Figure 4 lower
panel) as characterized previously [19], and WT aSyn
amyloid-like fibrils prepared after agitating aSyn (Figure 4,
lower panel). By using a sucrose gradient of 10 - 30%
and an exclusion layer (60% sucrose) under the gradi-
ent, WT aSyn monomers were clearly detected in the low
density factions 16 - 22. HNE-aSyn and n-aSyn containingFigure 4 SDGC analysis of recombinant WT, H50Q, and H50R aSyn. Re
factions from 16 to 22 (row 1 of the upper panel). Oligomerized aSyn is ch
exemplarily displayed by HNE-aSyn and n-aSyn consisting of oligomeric aS
in the first exclusion fractions (row 3 of the lower panel). H50 mutations (H
exclusion fraction (arrows, rows 2 and 3 of the upper panel).oligomers showed a shift of aSyn positive fractions to
higher density fractions. Large aSyn aggregates like aSyn
fibrils were observed in the first exclusion fractions. We
next compared the aSyn positive fractions after SDGC
analysis of recombinant WT and aSyn H50 mutants pre-
pared from E. coli. In contrast to WT aSyn, a proportion
of aSyn H50 mutants was detected in the first exclusion
fraction with a high sucrose density (60%), indicating
an increased intrinsic aggregation propensity of H50Q/R
aSyn (Figure 4, upper panel).
To assess the potential existence of soluble, oligomeric
species in recombinant aSyn samples, we further ana-
lyzed WT and H50 mutant aSyn by using SEC. We did
not detect an intrinsic formation of soluble oligomers in
untreated WT aSyn and in both H50 aSyn mutants (data
not shown). Our previous studies have shown that increased
ROS/RNS induce the oxidation/nitration of aSyn. In par-
ticular, nitration of aSyn significantly promotes the
formation of soluble aSyn oligomers [19]. Thus, we asked
whether nitration-mediated aSyn oligomerization is influ-
enced by H50 mutations. Nitrated aSyn was generated by
incubating WT and H50Q/R aSyn with tetranitromethane
(TNM), an efficient nitrating agent [19]. Nitration triggered
the formation of soluble oligomers, which were readily de-
tected in WTaSyn as well as in H50Q/R mutants (Figure 5A).
Notably, the H50Q mutation significantly increased the
level of TNM-induced oligomeric aSyn compared to
WT aSyn (Figure 5B). The H50R mutation also increased
nitration-induced oligomerization of aSyn, albeit without
reaching statistical significance. This finding demonstrates
that H50 mutations exacerbate nitration-mediatedcombinant human WT aSyn is clearly detected in the low density
aracterized by a signal shift towards higher density fractions, which is
yn (rows 1 and 2 of the lower panel). Large fibrillar aggregates appear
50Q and H50R) increase aSyn immunosignal in the 60% high density
Figure 5 Nitration-induced oligomerization of WT aSyn and aSyn H50 mutants. A) Recombinant WT aSyn and aSyn H50 mutants were
treated with 5 mM TNM for 7 h to induce nitration-mediated oligomerization of aSyn. Formation of soluble aSyn oligomers after TNM treatment
was assessed by SEC. aSyn monomers (M) and oligomers (O) are distinguished by different retention times. B) Quantification of soluble oligomers
was performed by calculating the area ratio of oligomeric fraction to monomeric fraction. H50 mutations increase the formation of soluble
oligomers after TNM treatment. Particularly, the H50Q mutation significantly enhances the propensity of nitration-mediated aSyn oligomerization.
Significance was determined by a one way ANOVA Tukey’s Multiple Comparison Test. n = 3. Error bars = SEM.
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of aSyn H50 mutants under oxidative stress conditions.
In order to study the propensity of H50 mutants to
form amyloid fibrils, we generated aSyn fibrils by agitating
WTand H50Q/R mutant aSyn at 37°C for 7 days. Electron
microscopy (EM) analysis revealed that WT and H50Q/RFigure 6 Fibrillization of WT and H50 mutant aSyn. A) EM analysis of fi
7 days. B) Recombinant WT and H50Q/R aSyn were agitated for 7 days wit
fibrils was assessed by ThT assay. ThT intensity was normalized to non-agita
significantly increases the formation of aSyn fibrils with and without NaCl. S
Comparison Tests. n = 6 (-NaCl), n = 8 (+NaCl). Error bars = SEM.aSyn form fibrillar structures after agitation (Figure 6A).
Assessment of amyloid fibrils using Thioflavin T (ThT)
assay demonstrated that H50Q aSyn significantly increases
fibrillization compared to WTaSyn both in the absence or
presence of NaCl (Figure 6B). The influence of the
H50R mutation on aSyn fibrillization was dependentbrils derived from recombinant WT and H50Q/R aSyn agitated for
h (+NaCl) and without (-NaCl) 160 mM NaCl. The formation of aSyn
ted, monomeric WT aSyn (M, dashed line). H50Q aSyn mutation
ignificance was determined by one way ANOVA Tukey’s Multiple
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the presence of 160 mM NaCl at a physiological ionic
strength the H50R mutant also showed an increase in
fibrillization of aSyn, although not reaching statistical
significance.
Complementary assessments of aSyn aggregation
in vitro revealed that compared to WT aSyn, H50 mu-
tant aSyn is more prone to form 1) high density aggre-
gates (SDGC), 2) soluble oligomers after exposure to a
nitrating agent (SEC), and 3) amyloid fibrils after agita-
tion (ThT assay), suggesting a general enhanced aggrega-
tion propensity due to H50 mutations. Thus, we asked if
H50 mutations also increase the aggregation propensity
of intracellularly expressed aSyn. To this end, we transi-
ently transfected H4 cells with WT and H50Q/R aSyn
constructs. The lysates of transfected cells were analyzed
by SDGC followed by dot blot analysis. In the lysates of
H50Q aSyn transfected cells, we observed a shift of aSyn
immunoreactivity from lower to higher density fractions
compared to WT aSyn, particularly in fractions 11 - 17
(Figure 7). Quantification of aSyn immunointensity from
independent analyses revealed a reproducible increase in
the aSyn signal in these fractions of higher density for
H50Q aSyn samples, confirming an increased oligome-
rization propensity of cellularly expressed H50Q mutant
aSyn (Figure 7 lower panel). In contrast to the H50Q
mutant, the H50R mutant did not show an obvious in-
crease in the aSyn signal in the higher density fractions
11 - 17.Figure 7 Intracellular aggregation of WT and H50 mutant aSyn. H4 ne
SDGC analysis of lysates from H4 cells transfected with WT and H50Q/R mu
density fractions to higher density fractions was observed for the aSyn H50
11 - 17 in 3 independent experiments is shown in the lower panel. To allo
each experiment were loaded on the same dot blot membrane. The relativ
fraction to the intensity of the fraction 17 from WT aSyn in each experimenOverexpression of H50 mutant aSyn increases cell
damage
To elucidate whether mutation of H50 increases cyto-
toxicity of aSyn, we transiently transfected H4 cells with
WT and H50Q/R aSyn constructs. Cell damage was
assessed by MTS viability assay and ToxiLight toxicity
assay. H4 cells transiently transfected with H50 aSyn
mutants showed a slight reduction in cell viability and
an increase in cell death compared to H4 cells trans-
fected with WT aSyn (Figure 8A). As viability and tox-
icity assays such as MTS and ToxiLight only determine
general damage of transiently transfected cells including
overexpressing and non-overexpressing cells, we also
used ICC to detect apoptosis specifically in aSyn over-
expressing cells (Figure 8B). The number of cells double
positive for aSyn and activated (cleaved) Caspase 3
(aCasp3) (aSyn+/aCasp3+) among all aSyn+ cells was de-
termined. Overexpression of H50Q/R mutants led to a
significant increase in the ratio of cells double positive
for aCasp3 and aSyn as compared to the overexpression
of WT aSyn, indicating that intracellular overexpression
of H50 mutants promotes apoptosis (Figure 8B).
Since our results showed that overexpression of H50Q/R
mutant aSyn attenuates cell susceptibility to HNE as com-
pared to WT aSyn (Figure 3, Additional file 1: Figure S2),
we asked whether overexpression of H50 mutant aSyn
would differently impact the response of cells to another
oxidative stressor, e.g. H2O2. Therefore, we analyzed the
influence of overexpression of WT and H50Q/R mutanturoglioma cells were transfected with WT and H50Q/R mutant aSyn.
tant aSyn was performed. A shift of aSyn positive fractions from lower
Q mutant. The quantification of aSyn immunointensity in fractions
w comparison, all fractions collected from WT and H50Q/R mutants in
e aSyn intensity was generated by normalizing the intensity of each
t.
Figure 8 Toxicity of intracellularly overexpressed WT and H50 mutant aSyn. A) H4 neuroglioma cells were transiently transfected with
mock, WT, and H50 mutant aSyn, and cell damage was assessed by using MTS cell viability (left) and ToxiLight assays (right). For quantification,
measured values were normalized to the mean of WT samples. The background levels of viability and toxicity of mock transfected cells are
indicated as dashed lines. Both assays show a slight increase in general cell damage in cells transfected with either H50Q or H50R aSyn.
Significance was determined by a one way ANOVA Tukey’s Multiple Comparison Test for randomized block experiments. n = 8 (ToxiLight) and
n = 12 (MTS assay). Error bars = SEM. B) The induction of apoptosis by overexpressed H50 mutant aSyn was assessed by ICC using antibodies
against aSyn (green) and activated Caspase 3 (aCasp3, red). The number of apoptotic, (aCasp3+ aSyn+, arrow) out of total aSyn overexpressing
cells (aSyn+) was counted. The proportion of apoptotic cells in H50Q/R aSyn overexpressing cells was significantly higher than in WT aSyn
overexpressing cells. For quantification, measured values were normalized to the mean of WT samples. Significance was determined by a one
way ANOVA Tukey’s Multiple Comparison Test for randomized block experiments. n = 6. Error bars = SEM. C) H4 cells transfected with mock, WT,
and H50 mutant aSyn were treated with H2O2 24 h after transfection for another 24 h followed by MTS viability assay. The viability of treated cells
was compared to the viability of the corresponding untreated cells (vehicle, dashed line). H2O2 treatment induces a more pronounced reduction
of the viability of H50Q/R overexpressing cells than of WT overexpressing cells. Significance was determined by two way ANOVA Bonferroni
Multiple Comparisons. n ≥ 3. Error bars = SEM.
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inducer of oxidative stress. Application of H2O2 induced
a concentration-dependent decrease in the viability of
H4 cells transfected with WT and H50Q/R mutant aSyn
(Figure 8C). In order to focus on the potential differencesin the susceptibility to H2O2 and thus, to eliminate base-
line toxic effects induced by overexpression of H50 mu-
tant aSyn, the fold reduction in the viability of transfected
cells was calculated compared to the corresponding
vehicle-treated cells. We observed that the H2O2 induced
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H50Q/R aSyn than in WT aSyn transfected cells at a
H2O2 concentration range of 100 – 500 μM. This effect
was statistically significant when using a lower H2O2
concentration of 100 μM. This finding suggests that
H50 mutations increase the cellular susceptibility to
oxidative stress.
Discussion
In the present study, we used a dual approach to alter
the H50 residue of aSyn, i.e. HNE-PTM and DNA
mutation-induced H50 substitution. We provide an
in vitro and cell-based characterization of the impact of
these alterations on aSyn aggregation and toxicity, two
important features of aSyn pathology, which are crucial
for the pathogenesis of PD.
The relevance of HNE modification of aSyn in the patho-
genesis of PD is strengthened by several lines of evidence: 1)
Oxidative stress and lipid peroxidation are strongly associ-
ated with neurodegeneration in PD. HNE along with other
reactive aldehyde products, such as glyoxal, malondialdehyde,
and 4-oxo-2-nonenal (ONE), are important products of lipid
peroxidation [18]; 2) The level of HNE-modified proteins is
enhanced in affected brain areas, particularly in aSyn con-
taining LBs in PD and other neurodegenerative disorders
with LB pathology [24-26]; 3) Several studies have shown
that HNE readily modifies aSyn in vitro and in cells exposed
to HNE [19,20,22]; and 4) HNE modification not only in-
creases aggregation propensity of aSyn in vitro, but HNE-
modified aSyn also provokes neuronal damage when applied
extracellularly to neurons [19-21]. However, the role of the
different HNE target sites of aSyn in these HNE-mediated ef-
fects (e.g. aSyn modification, aggregation, and toxicity) has
not yet been clarified. Among the possible target sites of
HNE, H50 is of particular interest, because a novel aSyn
point mutation affecting this residue (H50Q) has recently
been reported in monogenic PD patients.
To elucidate the role of H50 in HNE aSyn modifica-
tion, we analyzed HNE-treated WT and H50Q/R aSyn
by using MALDI-TOF MS. The analysis of GluC-
digested aSyn variants showed that the H50Q/R muta-
tions completely abolish the modification of residue 50.
Importantly, substitution of H50 remarkably reduced
the susceptibility of aSyn to HNE modification, indicat-
ing that H50 is the initial and most reactive residue of
aSyn for HNE addition. We have previously shown that
HNE-modified aSyn is more prone to form soluble
oligomers [19]. Here, we observed significantly reduced
formation of oligomers in H50 mutant aSyn compared
to WT aSyn by using complementary assays for the
analysis of oligomerization, i.e. SEC for the detection of
soluble oligomers and SDS-PAGE for the detection of
SDS-resistant oligomers. These findings suggest that
H50 not only increases the reactivity of aSyn to HNEaddition, but also plays a crucial role in HNE-induced
aSyn oligomerization.
Based on previous findings showing that HNE modi-
fication increases the cytotoxicity of extracellularly ap-
plied aSyn [19-21] and that extracellular application of
HNE causes HNE modification of intracellularly
expressed aSyn [22], we hypothesized that overexpres-
sion of aSyn increases the susceptibility of cells to HNE
due to the formation of intracellular H50-dependent
HNE-aSyn modification. To verify this hypothesis, we
overexpressed WT and H50Q/R aSyn in H4 cells and
compared cell susceptibility to HNE by using two com-
plementary methods, i.e. MTS viability assay and flow
cytometric analysis. Our results indicate that the sub-
stitution of H50, the most reactive residue for HNE
modification, reduces the susceptibility of aSyn overex-
pressing cells to HNE-induced toxicity. Thus, our experi-
ments not only provide evidence that H50 plays a crucial
role for HNE-mediated modification and oligomerization
of aSyn, but also suggest its implication in HNE-induced
cytotoxicity, probably due to HNE modification of intra-
cellular aSyn at the H50 residue.
The identification of the novel PD-associated aSyn
H50Q mutation provides evidence for the relevance of
aSyn H50 not only in sporadic but also in monogenic
PD. Thus, we asked whether the H50 mutations intrin-
sically potentiate aSyn pathology, despite reducing HNE-
mediated aSyn aggregation and toxicity, thereby support-
ing the pathogenicity of the novel reported H50Q muta-
tion. We analyzed the effects of H50 mutations on aSyn
aggregation both in vitro using recombinant human aSyn,
and in aSyn overexpressing cells. Analysis of the formation
of amyloid fibrils in agitated aSyn samples using ThT assay
demonstrated that H50Q mutation significantly increases
the fibrillization of aSyn compared to WT aSyn, which is
consistent with recent in vitro studies [27-29]. In con-
trast to a recent study [30], H50R did not significantly
reduce fibrillization compared to WT aSyn in our exper-
iments, likely due to different conditions for the fibrilli-
zation experiments (e.g. starting concentration of
monomeric aSyn and buffer composition). In our study,
the salt concentration in the aggregation buffer influ-
enced the impact of the H50R aSyn mutation on fibrilli-
zation. Under physiological salt concentrations, H50R
aSyn also showed higher fibrillization levels than WT
aSyn, although less pronounced than H50Q aSyn. Con-
sistently, we detected aSyn H50Q/R in the first high
density fractions of SDGC, analogous to amyloid fibrils.
These findings indicate that H50Q/R mutations intrin-
sically increase the propensity of aSyn to form larger
aggregates. Yet, accumulating evidence suggests that
small aggregation intermediates, especially oligomeric
aSyn species, may be more toxic than large amyloid
fibrils [31-33]. Therefore, in addition to fibrillization, we
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tect soluble oligomers in unmodified recombinant WT
aSyn and H50Q/R mutants by applying SEC. However,
we were able to show that H50Q/R mutations, particu-
larly the H50Q mutation, increased the formation of
soluble aSyn oligomers in the presence of a nitrating
agent, indicating that H50 mutant aSyn is more prone
to form soluble oligomers under oxidative stress, char-
acterized by accumulating ROS/RNS. Recently, it was
shown that the H50Q mutation leads to a chemical shift
within the C-terminal region (residue 135-140) of aSyn
[30], affecting tyrosine 136, one target site for nitration
[19]. Thus, H50 mutation may directly influence the
accessibility or reactivity of this tyrosine residue to ROS/
RNS, and consequently increase oligomerization propen-
sity of aSyn in response to oxidative stress.
To validate our in vitro observation concerning the
influence of H50 mutations on aSyn aggregation, we an-
alyzed the impact of these mutations on intracellularly
overexpressed aSyn in H4 cells. In a very recent study, in
which the oligomerization of various aSyn mutants/vari-
ants was examined in HEK cells by using Bimolecular
Fluorescence Complementation (BiFC) assay, no signifi-
cant differences between WT and H50Q aSyn have been
detected [34]. Interestingly, we observed an increase in
H50Q aSyn immunosignal in higher density fractions of
SDGC, suggesting an enhanced formation of oligomeric
aSyn species in H4 cells. Taken together, our in vitro and
cell-based experiments suggest that H50Q mutation in-
trinsically increases aggregation propensity of aSyn when
compared to WT. Yet, while H50Q aSyn tends to form
larger fibrillar aggregates in vitro as revealed by ThT and
SDGC analysis, intracellularly overexpressed H50Q aSyn
is more prone to the formation of oligomeric species as
indicated by SDGC analysis. This discrepancy may be at-
tributed to the presence of cellular factors that impact the
aggregation kinetics of aSyn in cells, which is in accord-
ance to our in vitro finding that additional treatment of
aSyn with a nitrating agent increases the propensity of
H50 mutant aSyn to form oligomers. Moreover, protein
degradation pathways may also influence aSyn aggrega-
tion. In particular, we have recently shown that oligomeric
and higher aggregated aSyn species are differently proc-
essed by autophagy as a major protein degradation path-
way [33]. Therefore, intracelluar oligomerization of H50
mutant aSyn may be affected by autophagy associated
pathways, which would be important to address in future
studies.
To study the toxic effect of intracellularly expressed
aSyn H50 mutants, we overexpressed WT and H50Q/R
aSyn mutants in H4 cells by transient transfection. We
generally observed a slight increase in cell damage due
to H50Q/R mutations as measured either by ToxiLight
toxicity or by MTS viability assay. In a more specificassessment of the direct effect of overexpressed aSyn on
toxicity, we focused on aSyn overexpressing cells and an-
alyzed the proportion of apoptotic cells among aSyn+
cells (aCasp3+/aSyn+). This specific cell death assay and
the cell experimental conditions used in this study
allowed us to detect a more pronounced toxic effect
evoked by intracellularly overexpressed H50Q/R mu-
tants, which was not revealed in other recent studies on
pathological cellular effects of H50Q mutation [27,28].
We furthermore analyzed the influence of H50Q/R muta-
tion on the H2O2-induced reduction of cellular viability.
Our results showed that overexpression of H50Q/R mu-
tant aSyn increases cellular susceptibility to H2O2 com-
pared to WT aSyn. This finding is in agreement with a
previous study observing this effect for H50Q aSyn in an-
other cell model [27]. Using a H2O2 concentration range
between 100 - 500 μM, we noticed that the increase in cel-
lular susceptibility to oxidative stress due to H50Q/R mu-
tation is especially marked at a lower H2O2 concentration
(i.e. 100 μM) when compared to WT aSyn. The difference
in cellular susceptibility between aSyn H50 mutants and
WT aSyn declines with increasing H2O2 concentrations
(i.e. 200 - 500 μM). This might be explained by the oc-
currence of global damage under strong oxidative stress
conditions. Thus, our results suggest that the aSyn H50
mutation particularly increases cellular susceptibility at
comparatively low levels of oxidative stress. Taking into
account that oxidative stress conditions potentiate the
formation of aSyn oligomers in H50 mutant aSyn (par-
ticularly H50Q aSyn) in vitro, our study indicates that
the increased toxicity of H50Q/R mutant aSyn under
oxidative stress might be associated with the formation
of toxic oligomeric aSyn species.
Interestingly, H50Q/R mutant aSyn differentially influ-
ences cellular response to HNE and H2O2. Both stressors
trigger cell death in a dose-dependent manner. However,
while H50Q/R overexpressing cells appear to be more
resistant to HNE than the WT aSyn overexpressing
cells, they are more vulnerable to H2O2. These findings
emphasize the role of H50 as an important HNE modi-
fication site in HNE-mediated toxicity, with particular
relevance for sporadic PD. Additionally, the increased
susceptibility to H2O2 due to H50 mutations suggests
that the mechanistic role of the H50Q mutation in
monogenic PD may rely on an altered neuronal re-
sponse to general oxidative stress. To clarify whether
H50 mutation generally increase cellular susceptibility
to insults or whether this effect is specific to oxida-
tive stress, further extensive studies are needed ana-
lyzing the impact of H50Q mutation under more
specified oxidative stress and non-oxidative stress related
conditions.
In this study, we substituted H50 by two amino acid
residues with different chemical characteristics, i.e. the
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(like histidine). Both mutations impact aggregation be-
havior and toxicity of aSyn, although to a different extent.
Thus, our results suggest that the effects of the PD-related
H50Q mutation are attributed to the loss of a functional
H50 residue rather than to a specific gain of function in-
duced by the glutamine. Nevertheless, the H50R mu-
tation appeared to be more toxic than the H50Q
mutation, although H50R aSyn was less prone to ag-
gregation than H50Q aSyn in vitro, and increased
intracellular aggregation of H50R aSyn was not de-
tectable by using SDGC. These interesting findings
suggest that besides aggregation, other mechanisms
affecting the physiological or pathological function of aSyn
have to be considered when investigating H50-mutation
dependent toxicity.
Conclusion
Our data demonstrate that aSyn H50 alterations, ei-
ther by oxidative stress-related HNE modification or
by gene mutation, increase aggregation propensity
and cytotoxicity of aSyn (Figure 9). Moreover, we re-
veal that oxidative stress not only triggers aSyn path-
ology by directly modifying H50 of WT aSyn via
HNE addition, but also potentiates the pathological
effects of the H50Q mutation. Although H50Q muta-
tion diminishes the HNE-mediated effects on aSyn, it
intrinsically increases aSyn aggregation and toxicity,
and exacerbates the cellular susceptibility to oxidative
stress, especially to ROS/RNS other than the lipid
peroxidation product HNE. Thus, we provide novel
insights into the mechanisms underlying oxidative
stress-associated pathogenesis of sporadic and H50Q-
associated monogenic PD.Figure 9 Summary of the impact of aSyn H50 modification and mutaMethods
Site-directed mutagenesis
The QuikChange® Site-directed Mutagenesis Kit (Agilent
Technologies, Waldbronn, Germany) was applied to gen-
erate both aSyn H50Q/R mutations in the coding se-
quence of WT aSyn in human aSyn pcDNA3.1 and pT7-7
constructs according to the manufacturer’s protocol. The
mutation-covering, complementary primer sequences 5′
G GAG GGA GTG GTG CAG GGT GTG GCA ACA G
3′ and 5′ C TGT TGC CAC ACC CTG CAC CAC TCC
CTC C 3′, as well as 5′ G GAG GGA GTG GTG CGT
GGT GTG GCA ACA G 3′ and 5′ C TGT TGC CAC
ACC ACG CAC CAC TCC CTC C 3′ were used to gener-
ate aSyn H50Q and H50R mutations, respectively.
Preparation of recombinant human aSyn and induction of
PTMs
Constructs containing WT aSyn and aSyn H50 mutants
were transformed in E. coli BL21 (DE3) pLys competent
cells (Novagen, San Diego, CA, USA). The preparation
and purification of recombinant WT and H50Q/R mu-
tant aSyn were performed as previously described [19].
To induce nitration, recombinant aSyn of 70 μM was
incubated with 5 mM tetranitromethane (TNM) in 30 mM
Tris/HCl pH 7.4 at room temperature (RT) for 7 h. HNE-
modified aSyn was generated by incubating aSyn with
HNE concentrations ranging from 50 μM to 3000 μM in
30 mM Tris/HCl pH 7.4 at 37°C for 24 h.
Mass spectrometry
Detection of HNE-modified aSyn was performed by
matrix-assisted laser-desorption-ionization time-of-flight
mass spectrometry (MALDI-TOF MS) as previously
described [19]. Briefly, for the digestion with GluCtion on aSyn pathology.
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Germany) 3-5 μg recombinant aSyn and 500 ng GluC
was dissolved in 50 mM NH4HCO3 and incubated over-
night at RT. Full-length aSyn or GluC-digested protein
samples were mixed with 0.1% trifluoroacetic acid (TFA)
(v/v) and MALDI matrix 2,5-dihydroxyacetophenone,
spotted on a stainless steel target, and measured by a
Bruker Autoflex (Bruker Daltonik, Bremen, Germany).
Positive ions were analyzed in reflector mode after ac-
celeration by 20 kV. External calibration was performed
using a peptide calibration standard (Bruker Daltonik).
Each displayed mass spectrum was produced by five
individual spectra, which were generated by 50 shots/
individual spectrum recorded from several positions
on a spot. Spectra were analyzed using Flex Analysis
software (Bruker Daltonik). Mass of aSyn ions or GluC-
digested aSyn fragments are given in the mass of singly
charged [M+H]+ ions.
Size exclusion chromatography
Size exclusion chromatography (SEC) was applied to
assess soluble oligomeric aSyn. Prior to SEC, samples
were centrifuged at 100000 g for 60 min. aSyn species
were separated on a SuperdexTM 75 10/300 column (GE
Healthcare, Freiburg, Germany) using 30 mM Tris/HCl,
0.2 M NaCl, pH 7.4 as an eluent at a flow rate of 0.5 ml/
min and monitoring the UV absorbance at 280 nm. To
ensure reproducibility between SEC runs, Gel Filtration
Standard (Bio-Rad Laboratories, Munich, Germany) was
used prior to each set of analysis.
In vitro fibrillization of aSyn and Thioflavin T assay
WT and H50Q/R mutant aSyn of 70 μM in 30 mM
Tris/HCl pH 7.4 (100 μl per sample) were incubated in a
96-well plate and agitated at 200 rpm on a Controlled
Environmental Incubator Shaker (New Brunswick Scien-
tific INC, New Brunswick, NJ, USA) at 37°C for 7 d in the
presence of glass beads with a diameter of 2 mm. For the
detection of aSyn fibrils, 6 μg of agitated aSyn was diluted
in 30 mM Tris/HCl pH 7.4 containing 20 μM ThT
(Sigma-Aldrich, Taufkirchen, Germany) and incubated for
10 min at 300 rpm and RT in the dark. The fluorescence
intensities were measured in a Varian Cary Eclipse
fluorescence spectrophotometer (Agilent Technologies,
Waldbronn, Germany) with an excitation at 445 nm and
an emission at 480 nm. For quantification, values were
normalized to the fluorescence intensity of non-agitated
WTaSyn.
Electron microscopy
Electron microscopy (EM) was performed to analyze
fibrillization of WT and H50 mutant aSyn. For negative
staining, 10 μl of each agitated aSyn sample at a concen-
tration of 70 μM were adsorbed onto glow-dischargedcarbon-coated Formvar grids (Electron Microscopy Sci-
ences, Hatfield, PA, USA), incubated for 20 min, washed
with distilled water, and then stained with a filtered 3%
aqueous uranyl acetate solution for 5 min. After another
washing step, grids were dried and analyzed with a
transmission electron microscope (LEO 906E; Carl Zeiss,
Oberkochen, Germany).
Cell culture, calcium-phosphate transfection, and cell
treatment
H4 neuroglioma cells of human origin (ATCC, HTB-148)
were maintained in Opti-MEM+GlutaMAX (51985-042,
Invitrogen, Darmstadt, Germany) supplemented with 10%
fetal calf serum (FCS; 10270-106, Invitrogen, Darmstadt,
Germany) at 37°C. 24 h prior transfection cells were
plated in 24-well plates (3.5 × 104 cells/well) or in 6-well
plates (2 × 105 cells/well) and cultured in 0.5 ml or 2 ml
medium, respectively. Calcium-phosphate transfection
was performed as previously described [35]. Equimolar ra-
tios of pcDNA3.1 plasmids encoding human WT, H50Q,
and H50R aSyn were transfected under a cytomegalovirus
promoter. Mock transfection without adding plasmid
DNA served as control. The transfection efficiency was
controlled by using flow cytometry. For the treatment
experiments, H4 cells were exposed to different con-
centrations of HNE (50 – 3000 μM, Cayman Chemical
Company, Ann Arbor, MI, USA) or H2O2 (100 - 500 μM,
Merck, Darmstadt, Germany) 24 h after transfection for
12 h (HNE) or 24 h (H2O2), respectively. The stock solu-
tion of 64 mM HNE was prepared in ethanol. The stock
solutions of HNE and H2O2 were freshly diluted in culture
medium prior to treatment. Vehicle controls (ethanol
or culture medium) were prepared in accordance to
the highest HNE and H2O2 concentration used for the
treatments.
Detection of aSyn transfection efficiency and expression
levels via flow cytometry
H4 cells were seeded in 24-well plates (3.5 × 104 cells per
well), transfected with pcDNA3.1 expression vectors
encoding WT and H50Q/R mutant aSyn, and harvested
24 h after transfection. Cells were washed with PBS and
fixed by using a 1:4 dilution of Fixation/Permeabilization
Concentrate (eBioscience, Frankfurt, Germany) in Fixation/
Permeabilization Diluent (eBioscience). Cells were washed
with Permeabilization Buffer (eBioscience) and blocked for
15 min by using 10 μl of FcR Blocking Reagent (human,
Miltenyi Biotech, Bergisch Gladbach, Germany). Detection
of aSyn was performed by applying a rat anti-human aSyn
primary antibody (1 h, 1:400, Enzo Life Sciences, ALX-804-
258-L001, Lörrach, Germany) and an Alexa488-labeled
donkey anti-rat secondary antibody (1 h, 1:800, A21208,
Invitrogen, Darmstadt, Germany) diluted in Permeabilization
Buffer. 20000 cells were detected to analyze aSyn
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signal via flow cytometry with a CyFlowR Space (Partec,
Münster, Germany) and the FloMax 2.81 analysis and
quantification software. The forward and sideward scatter
signal was used to determine the population of single cells
used for measurements. The cut-off fluorescence intensity
for defining aSyn expressing cells was set by measuring
mock transfected cells treated with the same staining
protocol.Assessment of toxicity and cell viability
Toxicity of aSyn transfected H4 cells was analyzed in
24-well plates by ToxiLight enzyme activity assay for
membrane integrity (Lonza, Basel, Switzerland), and MTS
viability assays (Promega, Mannheim, Germany) accord-
ing to the manufacturer’s protocol, 36 h and 48 h after
transfection, respectively.
In order to measure apoptotic cell death, activated
(cleaved) Caspase 3 positive cells were assessed by ICC.
For this, H4 cells were plated on 13 mm glass coverslips
prior to transfection. 36 h after transfection, cells were
fixed with 4% paraformaldehyde for 15 min. Cells were
washed with Tris buffered saline (TBS, pH 7.4) and
blocked with fish skin gelatin buffer (FSGB) containing
50 mM Tris/HCl, pH 7.4, 1% BSA, 0.2% fish skin
gelatin, and 0.1% Triton-X 100 for 1 h at RT. Cells were
incubated with primary rat anti-human aSyn (1:250,
Enzo Life Sciences, ALX-804-258-L001, Lörrach,
Germany) and rabbit anti-aCasp3 (1:500, 9661, Cell
Signaling Technology, Danvers, MA, USA) antibodies
overnight at 4°C. After washing, Alexa 488-labeled
donkey anti-rat secondary antibody (1:1000, A21208,
Invitrogen, Darmstadt, Germany) and Alexa 568-
labeled donkey anti-rabbit secondary antibody
(1:1000, A10042, Invitrogen) were applied for 1 h at
RT. Nuclei were counterstained with 4′6′-diamidino-
2-phenylindol (DAPI, 1:10000, D8417, Sigma-Aldrich,
Steinheim, Germany) for 15 min. After washing,
coverslips were mounted by using Prolong Antifade
reagent (P36930, Invitrogen). The ratio of cells posi-
tive for aCasp3 (aCasp3+) among aSyn positive (aSyn
+) cells was assessed in accordance to a systematic,
random counting procedure [19]. For image acquisi-
tion, Axio Imager M2 microscope combined with an
AxioCam MRm camera (Carl Zeiss AG, Jena, Germany)
with the same settings and exposure times within each in-
dependent experiment was used. Six images of each cover-
slip were randomly selected at 20 × magnification to
enable the analysis of at least 200 aSyn positive cells per
independent experiment. aSyn+ and aCasp3+ cells were
scored based on the presence of immunostaining com-
pared to the background staining of the corresponding
controls.SDS-PAGE and Western blot
For Western blot (WB) of recombinant aSyn, 0.5 μg
aSyn was mixed with one volume of SDS sample buffer
(0.125 M Tris/HCl pH 6.8, 4% SDS, 20% glycerol), sepa-
rated on 15% SDS-PAGE, and blotted onto nitrocellulose
membranes (Millipore, Darmstadt, Germany). The blots
were probed with a mouse anti-aSyn primary antibody
(Syn-1, 1:2000, BD Transduction Laboratories, San
Diego, CA, USA) or a rabbit anti-aSyn antibody (SNCA
antibody, 1:2000, Proteintech Europe, Manchester, UK).
While Syn-1 was generated using aSyn fragment amino
acids 15-123 as antigen, SNCA antibody was raised
against full-length aSyn. The nitrocellulose mem-
branes were subsequently probed with secondary goat-
anti-mouse antibody or goat anti-rabbit antibody coupled
to horseradish peroxidase (1:10000 Dianova, Hamburg,
Germany). For the detection of proteins, membranes were
incubated with the SuperSignal West Pico or Femto Sensi-
tivity Substrate™ (Thermo Scientific Rockford, lL, USA).
Immunoblots were visualized by VersaDoc gel imaging
system (BioRad, Munich, Germany).Sucrose density gradient centrifugation and dot blot
Sucrose density gradient centrifugation (SDGC) was per-
formed as previously described [36] with minor modifica-
tions. Briefly, a continuous 10 - 30% sucrose gradient
(30 ml) in 25 mM Tris-HCl, pH 7.4, 0.2 M NaCl was
prepared on top of the 60% sucrose cushion (4 ml). For
analyzing recombinant aSyn samples, 30 μg of aSyn was
loaded on top of the sucrose gradient. For analyzing aggre-
gation of cellular expressed aSyn, H4 cells were seeded in a
6 well plate (2 × 105 cells per well) for transfection. Cells
from 3 wells were collected 36 h after transfection via
scraping in ice-cold PBS containing protease/phosphatase
inhibitors and pooled for SDGC analysis. Subsequently, cell
pellets were homogenized in 50 mM Tris/HCl pH 7.4 buf-
fer containing 150 mM NaCl, 2 mM EDTA, 1% (v/v) NP-
40, 0.1% (w/v) SDS, and complete mini protease inhibitors
cocktail (Roche Diagnostics GmbH) in a Potter dounce
homogenizer at 4°C. The lysates were loaded on top of the
sucrose gradient. After centrifugation in a Beckman L-70
Ultracentrifuge with a SW-28 rotor (Beckman Coulter,
Brea, CA, USA) at 26000 rpm for 18 h at 4°C, 22 sucrose
fractions with 1.5 ml each were collected. 400 μl of each
fraction were mixed with 100 μl methanol and spotted on
a nitrocellulose membrane. After blocking the nitrocellu-
lose membranes, aSyn was visualized using a mouse anti-
aSyn primary antibody (Syn-1, 1:2000, BD Transduction
Laboratories), and a HRP-conjugated goat anti-mouse sec-
ondary antibody (1:10000, Dianova). For the detection of
aSyn in SDGC fractions, membranes were incubated with
the SuperSignal West Pico or Femto Sensitivity Substrate™
(Thermo Scientific).
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Statistical analyses were performed using GraphPad Prism
(GraphPad Software, San Diego, CA, USA). All numeric
results are reported as mean + standard error of the mean
(SEM) and represent data from a minimum of three in-
dependent experiments unless otherwise stated. Signifi-
cant differences are depicted in the figures by graphical
representation. p < 0.05 was considered as significant =
*. p < 0.01 = **. p < 0.001 = ***.Additional file
Additional file 1: Figure S1. Determination of transfection efficiency by
flow cytometry. Figure S2. Analysis of the susceptibility of WT and H50
mutant aSyn overexpressing cells to HNE by flow cytometry.Abbreviations
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